Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0188 • ACR Convergence 2020
The Risk of Fractures in a Community-based Cohort of Patients with Rheumatoid Arthritis Compared with the Background Population
Lisa Theander¹, Jan Åke Nilsson², Minna Willim³, Lennart T.H. Jacobsson⁴ and Carl Turesson⁵, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Sweden, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁵Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden
Background/Purpose: Rheumatoid Arthritis (RA) has been associated with increased risk of osteoporosis and fractures. We have recently presented results on DXA measurements over 10 years…
Abstract Number: 0204 • ACR Convergence 2020
Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects
KyungSang Yu¹, InJin Jang¹, HyeongSeok Lim², JangHee Hong³, MinGul Kim⁴, MinKyu Park⁵, Anhye Kim⁶, MinSoo Park⁷, JaeYong Chung⁸, JongLyul Ghim⁹, SeungHwan Lee¹, SeokKyu Yoon², InSun Kwon³, Daniel Furst*¹⁰, Edward C Keystone¹¹, SangJoon Lee¹², SungHyun Kim¹², YunJu Bae¹², JungBin Cha¹³, HyeJin Kang¹³ and Jonathan Kay¹⁴, ¹Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea, ²College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Republic of Korea, ³Chungnam National University Hospital, Daejeon, Republic of Korea, ⁴College of Medicine, Jeonbuk National University, Jeonbuk, Republic of Korea, ⁵Chungbuk National University Hospital, Cheongju, Republic of Korea, ⁶CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea, ⁷Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁸Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁹Inje University Busan Paik Hospital, Busan, Republic of Korea, ¹⁰Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Celltrion, Inc., Incheon, Republic of Korea, ¹³Celltion, Inc., Incheon, Republic of Korea, ¹⁴University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 was developed as the first biosimilar of the high concentration (100 mg/mL), citrate-free formulation of reference adalimumab. The purpose of this study was…
Abstract Number: 0220 • ACR Convergence 2020
Impact of Concomitant Glucocorticoids on the Clinical Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: An Ad Hoc Analysis of Data from Three Phase 3 Studies
Bernard Combe¹, Frank Buttgereit², Andrew Östör³, Ricardo Xavier⁴, Alain Saraux⁵, Capucine Daridon⁶, Kirsten Famulla⁷, Yanna Song⁸, Ivan Lagunes-Galindo⁹ and Gerd Burmester¹⁰, ¹University of Montpellier, Montpellier, France, ²Charité University Medicine, Berlin, Germany, ³Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ⁴Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Rio Grande do Sul, Rio Grande do Sul, Brazil, ⁵Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ⁶AbbVie France, Rungis, France, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie Inc., North Chicago,, IL, ⁹AbbVie Inc., North Chicago, IL, ¹⁰Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Glucocorticoid (GC) therapy has strong anti-inflammatory effects and helps slow radiographic progression in RA1; however, GCs can be associated with adverse events (AEs) such…
Abstract Number: 0237 • ACR Convergence 2020
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis
Stanley Cohen¹, Ronald F Van Vollenhoven², Jeffrey Curtis³, Leonard Calabrese⁴, Cristiano AF Zerbini⁵, Yoshiya Tanaka⁶, Louis Bessette⁷, Casey Schlacher⁸, Tim Shaw⁹, John Liu⁹, Jeffrey Enejosa⁹, Yanna Song¹⁰ and Gerd Burmester¹¹, ¹Metroplex Clinical Research Center, Dallas, TX, ²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Cleveland Clinic, Cleveland, OH, ⁵Centro Paulista de Investigacao Clinica (CEPIC), Sao Paulo, Brazil, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁷Laval University, Quebec, Canada, ⁸AbbVie Inc., Lake Forest, IL, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago,, IL, ¹¹Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: The safety and efficacy of upadacitinib (UPA), an oral JAK inhibitor, was evaluated in the phase 3 SELECT clinical program, which included 5 randomized,…
Abstract Number: 0481 • ACR Convergence 2020
Subclinical Synovitis in Arthralgia: How Often Does It Result in Clinical Arthritis? A Longitudinal Study to Reflect on Starting Points for DMARD Treatment
Cleo Rogier¹, Fenne Wouters², Laurette van Boheemen³, Dirkjan van Schaardenburg⁴, Pascal de Jong¹ and Annette van der Helm - van Mil⁵, ¹Erasmus MC, Rotterdam, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, ⁴Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁵Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: According to guidelines, clinical arthritis is mandatory for diagnosing rheumatoid arthritis (RA). However, in the absence of clinical synovitis, imaging-detected subclinical synovitis is increasingly…
Abstract Number: 0572 • ACR Convergence 2020
Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial
Elise van Mulligen¹, Angelique Weel², Mieke Hazes³, Annette van der Helm - van Mil⁴ and Pascal de Jong¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus School of Health Policy & Management, Maasstad hospital, Erasmus MC, Rotterdam, Netherlands, ³Erasmus Medical Center, Rotterdam, Netherlands, ⁴Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: The benefits of tapering are a decreased risk of long-term adverse events and a reduction of health care costs, especially when bDMARDs are tapered.…
Abstract Number: 0746 • ACR Convergence 2020
HDL-bound yRNA-derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Qiong Wu¹, Quanhu Sheng¹, Joseph Solus¹, Danielle Michell¹, Kasey Vickers¹, Ryan Allen¹, C. Michael Stein¹ and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Small RNAs (sRNAs), including microRNAs (miRNAs) and yRNA-derived sRNAs (yDRs), are important gene regulators and markers of disease. HDL, while known for its anti-atherogenic…
Abstract Number: 0763 • ACR Convergence 2020
Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Nora Petrovská¹, Monika Gregová¹, Jiří Baloun², Petra Hánová², Karel Pavelka¹, Jiří Vencovský¹, Ladislav Šenolt¹ and Mária Filková¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: The presence of antibodies against citrullinated proteins (ACPA) significantly increases the risk of developing rheumatoid arthritis (RA). EULAR characterised individuals with arthralgia suspicious for…
Abstract Number: 0780 • ACR Convergence 2020
Subsets of Synovial Fluid Derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Kuninobu Wakabayashi¹, Takeo Isozaki¹, Shin Ohta² and Tsuyoshi Kasama³, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Koutou-ku Tokyo, Japan
Background/Purpose: In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) secrete inflammatory cytokines and chemokines, invade and degrade cartilage, and stimulate osteoclast that cause bone erosion. Recently,…
Abstract Number: 0797 • ACR Convergence 2020
Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
Adela Castro¹, Jesus Diaz² and Guillermo Quiceno³, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Janus Kinase (JAK) inhibitors have shown long term benefit in patients with active RA with inadequate response to conventional or biologic DMARDs (1). Due to…
Abstract Number: 0813 • ACR Convergence 2020
Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors
Karel Pavelka¹ and Zlatuše Křístková², ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
Background/Purpose: Seropositivity / seronegativity in RA may have influence on response to bDMARDs or tsDMARDs. There is incomplete knowledge of differences in efficacy of JAK…
Abstract Number: 0830 • ACR Convergence 2020
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³, Edward C Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
Abstract Number: 0974 • ACR Convergence 2020
Role of NR4A Nuclear Receptor Family in RA Synovial Ectopic Lymphoid Neogenesis Revealed by Single Cell Profiling
Nida Meednu¹, Fan Zhang², Katherine Escalera-Rivera¹, Elisa Corsiero³, Edoardo Prediletto³, Michele Bombardieri⁴, Edward DiCarlo⁵, Dana Orange⁶, Susan Goodman⁷, Laura Donlin⁸, Soumya Raychaudhuri², Costantino Pitzalis⁴, Andrew McDavid¹ and Jennifer Anolik¹, ¹University of Rochester Medical center, Rochester, NY, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Queen Mary University of London, London, England, United Kingdom, ⁴Queen Mary University of London, London, United Kingdom, ⁵Hospital for Special Surgery, New York, ⁶Rockefeller University, New York, ⁷Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁸Hospital for Special Surgery, Weill Cornell Medicine, New York
Background/Purpose: Ectopic lymphoid structures (ELS) have been observed in synovial tissue of rheumatoid arthritis (RA) patients but their functional relevance in the disease remains unclear.…
Abstract Number: 1011 • ACR Convergence 2020
Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study
Frank Behrens¹, Ulrich Prothmann², Thilo Klopsch³, Ann-Dörthe Holst⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ²Knappschaftsklinikum Saar, Püttlingen, Saarland, Germany, ³Rheumatological Practice, Neubrandenburg, Mecklenburg-Vorpommern, Germany, ⁴Specialist Practice for General Medicine incl. Rheumatology and Acupuncture, Ludwigslust, Mecklenburg-Vorpommern, Germany, ⁵Pfizer Pharma GmbH, Berlin, Berlin, Germany
Background/Purpose: Tofacitinib is an orally applied Janus kinase inhibitor, which is approved for rheumatoid arthritis (RA) treatment in the USA since 2012, so that ‘real…
Abstract Number: 1182 • ACR Convergence 2020
Increased Prevalence of Carotid Atherosclerosis in Postmenopausal Women with Rheumatoid Arthritis: A Case Control Study
Dionicio Ángel Galarza-Delgado¹, José Ramón Azpiri López², Iris Jazmín Colunga Pedraza³, Mayra Alejandra Reyes Soto³, Alejandra Pérez Villar³, Itzel Corina Zárate Salinas², Paola Fernanda Frausto Lerma³ and Salvador Lugo Pérez², ¹Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico, ²Cardiology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico, ³Rheumatology service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Mexico
Background/Purpose: Cardiovascular disease (CVD) is the primary cause of mortality in women in developed countries. CVD risk rises with age, yet for women there is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].